Abstract 157P
Background
Gastric cancer (GC) is among the most common malignancy worldwide. The UICC/AJCC TNM classification is the most commonly used classification system. For adequate N staging at least 15 lymph nodes should be retrieved. In some countries, this amount of lymph nodes is not met, which can lead to understaging. The phenomenon of stage migration is caused by an insufficient number of lymph nodes examined. In order to reduce stage migration, some investigators have proposed using the metastatic lymph node ratio (LNR), namely the ratio between positive lymph nodes compared with the total number of lymph nodes examined, as a new prognostic indicator for gastric cancer.
Methods
Total 116 patients who underwent upfront D2 gastrectomy between 2012 to 2017 were included. LNR has classified into 4 groups: LNR0; 0, LNR1; >0-0.13; LNR2; 0.14-0.40 and LNR3; 0.41-1. We have used Kaplan-Meier method to calculate survival rates and log rank test to compare survival curves between groups.
Results
Males (58.6%) were more common than females (41.4%). Mean age at presentation was 56.12 years. Most common mode of presentation was pain abdomen (53.8%). Most common location of tumor was distal part (81%). Most commonly done procedure was distal radical gastrectomy (56.9%) followed by subtotal gastrectomy (32.8%). Median number of lymph nodes isolated was 14. 54 patients received adjuvant chemotherapy while 32 patients adjuvant chemoradiation. At a median followup of 14 months (range, 2–78 months), overall 5-year survival was 23.75%. (Median survival: 24 months). The 5-year survival for Stages I–III was 100%, 26.25%, and 11.25%, respectively (P < 0.001). In the univariate analysis; sex (p < 0.05), tumor grade (p < 0.001), T stage (p < 0.001), N stage (p < 0.001), TNM stage (p < 0.001), and LNR (p < 0.001) were statistically significant. The multivariate analysis showed that tumor grade, T stage, N stage, TNM stage and LNR still had statistical significance. In subgroup analysis of patients with less than 15 obtained lymph nodes, LNR was still a significant predictor of survival.
Conclusions
LNR can estimate prognosis of patients who undergo D2 gastrectomy, regardless of the number of lymph nodes examined. Thus LNR may become a new indicator to evaluate prognosis after D2 gastrectomy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
490P - Outcomes of sequential epidermal growth factor receptor tyrosine (EGFR) tyrosine kinase inhibitor (TKI) therapy in patients with advanced non-small cell lung carcinoma (NSCLC)- a real-world institutional experience
Presenter: Yvonne Ang
Session: Poster display session
Resources:
Abstract
498P - An observational retrospective study to evaluate the incidence of acquired EGFR T790M resistance in NSCLC patients with EGFR mutation following progression after at least one prior EGFR TKI treatment in Taiwan: ARISE study
Presenter: Shang-gin Wu
Session: Poster display session
Resources:
Abstract
501P - Clinical characteristics and efficacy in non-small cell lung cancer patients with EGFR exon 20 insertion and EGFR amplification
Presenter: Xin Gao
Session: Poster display session
Resources:
Abstract
502P - Epidermal growth factor receptor tyrosine kinase inhibitor treatment response in advanced non-small cell lung cancer with uncommon mutations: A multicenter observational study
Presenter: Masaki Kanazu
Session: Poster display session
Resources:
Abstract
482P - Interim analysis from a phase IIIb, open-label study of afatinib in EGFR TKI-naïve patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC
Presenter: Filippo De Marinis
Session: Poster display session
Resources:
Abstract
483P - A phase IIIb, open-label study of afatinib in EGFR TKI-naïve patients with EGFR mutation-positive NSCLC: A biomarker analysis
Presenter: Rafael Rosell
Session: Poster display session
Resources:
Abstract
484P - Activity of afatinib in patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC and baseline brain metastases: Pooled analysis of three large phase IIIb trials
Presenter: Maya Gottfried
Session: Poster display session
Resources:
Abstract
491P - Clinical outcomes of leptomeningeal metastases in EGFR-mutant lung adenocarcinoma
Presenter: Chia-I Shen
Session: Poster display session
Resources:
Abstract
510P - Paclitaxel as continuation maintenance therapy in patients with advanced non-small cell lung cancer
Presenter: Suzy Gohar
Session: Poster display session
Resources:
Abstract
496P - Higher osimertinib introduction rate achieved by multiple repeated re-biopsy after acquired resistance to first/second generation EGFR-TKIs
Presenter: Taira Ninomaru
Session: Poster display session
Resources:
Abstract